^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anruixi (zuberitamab)

    i
    Other names: HS006, HS 006, RHCACD20MA, HS-006, RHCACD 20MA, RHCAD-20-MA
    Associations

    News

    Trials
    Company:
    Zhejiang Hisun
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    19d
    Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial. (PubMed, J Immunother Cancer)
    Zuberitamab (375 mg/m2) plus CHOP was non-inferior to R-CHOP regarding ORR but exhibited a higher CR rate and was well tolerated in CD20-positive, previously untreated Chinese patients with DLBCL.
    Clinical • P3 data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Anruixi (zuberitamab)
    30d
    A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy (clinicaltrials.gov)
    P2, N=135, Not yet recruiting, BioRay Pharmaceutical Co., Ltd.
    New P2 trial
    |
    cyclosporine • Anruixi (zuberitamab)